Gene editing pioneer Carl June at the University of Pennsylvania is back in the headlines. The academic investigator--heralded for his work on a gene editing technique now being tested for cancer--led a team of scientists who successfully used zinc finger nuclease (ZFN) technology from Sangamo to tailor their T cells, essentially locking a back door used by the lethal virus.
A team of U.S. and South African researchers has identified and cloned an antibody that targets one of the few unchanging regions of HIV.
A study of a vaginal ring for the prevention of HIV came back with mixed results. The ring, which delivers two drugs, was safe for 28 days, but only one of the antiretroviral drugs was effective in protecting against the virus.
Nanowerk reported that UCLA researchers have developed a Google Glass app that could enable instant, wireless diagnostic testing for HIV, types of cancer and other diseases.
A new discovery that explains how the body's immune system makes a potent antibody that blocks HIV infection may be an important step toward developing a vaccine against the virus.
For several years now, scientists working on an HIV vaccine have been focused on a small set of patients whose immune systems were able to generate rare antibodies able to vanquish most strains of the lethal virus. And over the weekend a team of scientists from South Africa and the U.S. say that one woman--dubbed CAP256-VRC26--may have offered a key to do just that.
Daktari Diagnostics is well underway with plans to raise between $25 million and $30 million in Series D financing, money that co-founder and CEO Bill Rodriguez said will help, in part, to expand manufacturing capacity for the company's new HIV test, which starts selling in Africa this quarter.
Chembio Diagnostics has signed a two-part deal with Malaysia's RVR Diagnostics to expand the reach of its rapid HIV and syphilis point-of-care tests, and potentially others down the line.
Crowdfunded HIV vaccine developer Immunity Project has gained traction over the past few months, with technology incubator Y Combinator's investment in the initiative sparking mainstream media coverage. The investment raised Immunity Project's profile, but this has brought increased scrutiny of its plans. Not everyone likes what they see.
Sedia Biosciences will use a new $1 million NIH grant to bring forward an HIV diagnostic test it hopes will better assess recently infected individuals and how advanced the virus has become inside the body.